Anhui Zhongren Technology

Anhui Zhongren Technology is a biopharmaceutical company based in Hefei, China, specializing in the development of innovative sustained-release drug delivery systems for oncology. The company's core expertise lies in interstitial chemotherapy, a localized treatment approach that utilizes biodegradable implants to deliver high concentrations of anti-cancer agents directly to tumor sites. Its flagship product, Fluorouracil Sustained-release Implants, is approved in China for the treatment of various solid tumors, including gastric and colorectal cancers. By focusing on localized delivery, the company aims to maximize therapeutic efficacy while significantly reducing the systemic toxicity associated with conventional chemotherapy. Anhui Zhongren Technology continues to expand its pipeline with other sustained-release formulations of established chemotherapeutic agents.